TISIDB

Summary
Symbol	LCP1
Name	lymphocyte cytosolic protein 1 (L-plastin)
Aliases	PLS2; CP64; L-PLASTIN; LC64P; plastin 2; HEL-S-37; L-plastin (Lymphocyte cytosolic protein 1) (LCP-1) (LC64P ......
Chromosomal Location	13q14.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm, cytoskeleton Cell junction Cell projection Cell projection, ruffle membrane Peripheral membrane protein Cytoplasmic side Note=Relocalizes to the immunological synapse between peripheral blood T-lymphocytes and antibody-presenting cells in response to costimulation through TCR/CD3 and CD2 or CD28 (PubMed:17294403). Associated with the actin cytoskeleton at membrane ruffles. Relocalizes to actin-rich cell projections upon serine phosphorylation (PubMed:16636079).
Domain	PF00307 Calponin homology (CH) domain PF13499 EF-hand domain pair
Function	Actin-binding protein (PubMed:16636079, PubMed:17294403, PubMed:28493397). Plays a role in the activation of T-cells in response to costimulation through TCR/CD3 and CD2 or CD28 (PubMed:17294403). Modulates the cell surface expression of IL2RA/CD25 and CD69 (PubMed:17294403).

> Gene Ontology [ TOP ]
Biological Process	GO:0002263 cell activation involved in immune response GO:0002285 lymphocyte activation involved in immune response GO:0002286 T cell activation involved in immune response GO:0002366 leukocyte activation involved in immune response GO:0007015 actin filament organization GO:0007159 leukocyte cell-cell adhesion GO:0010737 protein kinase A signaling GO:0022617 extracellular matrix disassembly GO:0030198 extracellular matrix organization GO:0031099 regeneration GO:0031100 animal organ regeneration GO:0031334 positive regulation of protein complex assembly GO:0032386 regulation of intracellular transport GO:0033157 regulation of intracellular protein transport GO:0042110 T cell activation GO:0043062 extracellular structure organization GO:0043254 regulation of protein complex assembly GO:0044089 positive regulation of cellular component biogenesis GO:0051017 actin filament bundle assembly GO:0051639 actin filament network formation GO:0051764 actin crosslink formation GO:0061572 actin filament bundle organization GO:0070486 leukocyte aggregation GO:0070489 T cell aggregation GO:0071593 lymphocyte aggregation GO:0071800 podosome assembly GO:0071801 regulation of podosome assembly GO:0071803 positive regulation of podosome assembly GO:1902115 regulation of organelle assembly GO:1902117 positive regulation of organelle assembly
Molecular Function	GO:0003779 actin binding GO:0051015 actin filament binding GO:0051020 GTPase binding
Cellular Component	GO:0001725 stress fiber GO:0001726 ruffle GO:0001891 phagocytic cup GO:0002102 podosome GO:0005884 actin filament GO:0005924 cell-substrate adherens junction GO:0005925 focal adhesion GO:0015629 actin cytoskeleton GO:0030055 cell-substrate junction GO:0030175 filopodium GO:0031252 cell leading edge GO:0031253 cell projection membrane GO:0031256 leading edge membrane GO:0032432 actin filament bundle GO:0032587 ruffle membrane GO:0042641 actomyosin GO:0097517 contractile actin filament bundle GO:0098858 actin-based cell projection

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	LCP1
Name	lymphocyte cytosolic protein 1 (L-plastin)
Aliases	PLS2; CP64; L-PLASTIN; LC64P; plastin 2; HEL-S-37; L-plastin (Lymphocyte cytosolic protein 1) (LCP-1) (LC64P ......
Chromosomal Location	13q14.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between LCP1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between LCP1 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
24009233	Chronic Lymphocytic Leukemia	Promote immunity	Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing. Our analysis unveiled lymphocyte cytosolic protein 1 (LCP1), a lymphocyte-specific target that is highly expressed in CLL. LCP1 plays a critical role in B-cell biology by crosslinking F-actin filaments, thereby solidifying cytoskeletal structures and providing a scaffold for critical signaling pathways. Small interfering RNA knockdown of LCP1 blocked migration toward CXCL12 in transwell assays and to bone marrow in an in vivo xenotransplant model, confirming a role for LCP1 in leukemia migration. In addition, we identify LCP1 as a membrane-associated target in CLL with confirmed pathogenic significance.

Summary
Symbol	LCP1
Name	lymphocyte cytosolic protein 1 (L-plastin)
Aliases	PLS2; CP64; L-PLASTIN; LC64P; plastin 2; HEL-S-37; L-plastin (Lymphocyte cytosolic protein 1) (LCP-1) (LC64P ......
Chromosomal Location	13q14.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of LCP1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	LCP1
Name	lymphocyte cytosolic protein 1 (L-plastin)
Aliases	PLS2; CP64; L-PLASTIN; LC64P; plastin 2; HEL-S-37; L-plastin (Lymphocyte cytosolic protein 1) (LCP-1) (LC64P ......
Chromosomal Location	13q14.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of LCP1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.083	0.863
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.519	0.825
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.237	0.894
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.012	0.975
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.103	0.961
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.161	0.954
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.4	0.539
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.632	0.769
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.165	0.945
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.6	0.402
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.378	0.662
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.083	0.61

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of LCP1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	2.7	1	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	3.4	0.3	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	0	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	0	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	LCP1
Name	lymphocyte cytosolic protein 1 (L-plastin)
Aliases	PLS2; CP64; L-PLASTIN; LC64P; plastin 2; HEL-S-37; L-plastin (Lymphocyte cytosolic protein 1) (LCP-1) (LC64P ......
Chromosomal Location	13q14.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LCP1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	LCP1
Name	lymphocyte cytosolic protein 1 (L-plastin)
Aliases	PLS2; CP64; L-PLASTIN; LC64P; plastin 2; HEL-S-37; L-plastin (Lymphocyte cytosolic protein 1) (LCP-1) (LC64P ......
Chromosomal Location	13q14.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LCP1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LCP1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	LCP1
Name	lymphocyte cytosolic protein 1 (L-plastin)
Aliases	PLS2; CP64; L-PLASTIN; LC64P; plastin 2; HEL-S-37; L-plastin (Lymphocyte cytosolic protein 1) (LCP-1) (LC64P ......
Chromosomal Location	13q14.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LCP1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	LCP1
Name	lymphocyte cytosolic protein 1 (L-plastin)
Aliases	PLS2; CP64; L-PLASTIN; LC64P; plastin 2; HEL-S-37; L-plastin (Lymphocyte cytosolic protein 1) (LCP-1) (LC64P ......
Chromosomal Location	13q14.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of LCP1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	LCP1
Name	lymphocyte cytosolic protein 1 (L-plastin)
Aliases	PLS2; CP64; L-PLASTIN; LC64P; plastin 2; HEL-S-37; L-plastin (Lymphocyte cytosolic protein 1) (LCP-1) (LC64P ......
Chromosomal Location	13q14.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between LCP1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	LCP1
Name	lymphocyte cytosolic protein 1 (L-plastin)
Aliases	PLS2; CP64; L-PLASTIN; LC64P; plastin 2; HEL-S-37; L-plastin (Lymphocyte cytosolic protein 1) (LCP-1) (LC64P ......
Chromosomal Location	13q14.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting LCP1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse LCP1